SI-BONE, Inc.

146 articles with SI-BONE, Inc.

• SI-BONE To Present at The Morgan Stanley 20th Annual Global Healthcare Conference

  8/23/2022

  SI-BONE, Inc. (Nasdaq: SIBN), a medical device company dedicated to solving musculoskeletal disorders of the sacropelvic anatomy, today announced that the company will be participating in the upcoming Morgan Stanley 20th Annual Global Healthcare Conference.

• SI-BONE, Inc. Reports Financial Results for the Second Quarter 2022

  8/8/2022

  SI-BONE, Inc., a medical device company dedicated to solving musculoskeletal disorders of the sacropelvic anatomy, reported financial results for the quarter ended June 30, 2022.

• SI-BONE To Report Second Quarter 2022 Financial Results on August 8, 2022

  7/18/2022

  SI-BONE, Inc. (Nasdaq: SIBN), a medical device company dedicated to solving musculoskeletal disorders of the sacropelvic anatomy, today announced it will report financial results for the second quarter of 2022 after market close on Monday, August 8, 2022.

• SI-BONE To Present at The Canaccord Genuity 42nd Annual Growth Conference 2022

  7/18/2022

  SI-BONE, Inc. (Nasdaq: SIBN), a medical device company dedicated to solving musculoskeletal disorders of the sacropelvic anatomy, today announced that Laura Francis, CEO, and Anshul Maheshwari, CFO will be presenting at the upcoming Canaccord Genuity 42nd Annual Growth Conference in Boston.

• SI-BONE, Inc. Announces FDA Clearance for Expanded Indication of the iFuse-TORQ® Implant System

  6/13/2022

  SI-BONE, Inc. (SIBN), (Nasdaq: SIBN), a Silicon Valley-based medical device company dedicated to solving musculoskeletal disorders of the sacropelvic anatomy, today announced an FDA clearance for iFuse-TORQ ® for pelvic fracture fixation, including acute, non-acute and non-traumatic fractures.

• SI-BONE, Inc. Receives FDA 510(k) Clearance for iFuse Bedrock Granite, a Breakthrough Pelvic Fixation and Fusion Technology

  5/31/2022

  SI-BONE, Inc., (Nasdaq: SIBN), a Silicon Valley-based medical device company dedicated to solving musculoskeletal disorders of the sacropelvic anatomy, announces FDA 510(k) premarket clearance of the iFuse Bedrock Granite Implant System (Granite).

• SI-BONE, Inc. Announces New Technology Add-On Payment for Breakthrough Adult Spinal Deformity Treatment

  4/19/2022

  SI-BONE, Inc. today announced that the Centers for Medicare and Medicaid Services (CMS) has proposed a New Technology Add-on Payment (NTAP) for the iFuse Bedrock Granite™ implant.

• SI-BONE To Report First Quarter 2022 Financial Results on May 9, 2022

  4/18/2022

  SI-BONE, Inc. (Nasdaq: SIBN), a medical device company dedicated to solving musculoskeletal disorders of the sacropelvic anatomy, today announced it will report financial results for the first quarter of 2022 after market close on Monday, May 9, 2022.

• SI-BONE To Present at BofA Securities 2022 Healthcare Conference

  4/18/2022

  SI-BONE, Inc. announced that the company will be participating in the upcoming 2022 Bank of America Healthcare Conference in Las Vegas.

• SI-BONE, Inc. Reports Fourth Quarter and Full Year 2021 Financial Results and Issues 2022 Revenue Guidance

  2/28/2022

  SI-BONE, Inc., a medical device company dedicated to solving musculoskeletal disorders of the sacropelvic anatomy, reported financial results for the quarter and full year ended December 31, 2021.

• SI-BONE To Report Fourth Quarter and Full Year 2021 Financial Results on February 28, 2022

  2/1/2022

  SI-BONE, Inc. today announced it will report financial results for the fourth quarter and full year 2021 after market close on Monday, February 28, 2022.

• SI-BONE Announces Revenue for the Fourth Quarter and Full Year 2021

  1/10/2022

  SI-BONE, Inc., a medical device company dedicated to solving musculoskeletal disorders of the sacropelvic anatomy, announced its preliminary and unaudited revenue for fourth quarter and full year 2021.

• SI-BONE to participate in 24th Annual Needham Virtual Growth Conference

  12/27/2021

  SI-BONE, Inc. today announced management is scheduled to participate in the following investor conference: 24th Annual Needham Virtual Growth Conference on Wednesday, January 12, 2022 at 5:00 p.m. Eastern Time / 2:00 p.m. Pacific Time.

• SI-BONE, Inc. Reports Third Quarter 2021 Financial Results and Updates 2021 Financial Guidance

  11/8/2021

  SI-BONE, Inc., a medical device company dedicated to solving musculoskeletal disorders of the sacropelvic anatomy, reported financial results for the quarter ended September 30, 2021.

• SI-BONE To Report Third Quarter 2021 Financial Results on November 8, 2021

  10/18/2021

  SI-BONE, Inc. (Nasdaq: SIBN), a medical device company dedicated to solving musculoskeletal disorders of the sacropelvic anatomy, today announced it will report financial results for the third quarter of 2021 after market close on Monday, November 8, 2021.

• SI-BONE, Inc. Announces UnitedHealthcare Adopts Exclusive iFuse Only Coverage for Minimally Invasive SI Joint Fusion

  10/11/2021

  SI-BONE, Inc. announced that UnitedHealthcare has changed its minimally invasive SI joint fusion policy from covering all devices to exclusively covering SI-BONE’s triangular iFuse Implants, effective October 1, 2021.

• SI-BONE to Participate in Upcoming Conferences

  8/23/2021

  SI-BONE, Inc.today announced that it will be participating in the following upcoming investor conferences: 19 th Annual Morgan Stanley Global Healthcare Conference Fireside Chat on Tuesday, September 14, 2021, 12:30 p.m. Eastern Time / 9:30 a.m. Pacific Time.

• SI-BONE, Inc. Reports Second Quarter 2021 Financial Results and Announces Exclusive Coverage from Anthem

  8/2/2021

  SI-BONE, Inc., a medical device company dedicated to solving musculoskeletal disorders of the sacropelvic anatomy, reported financial results for the quarter ended June 30, 2021.

• SI-BONE, Inc. Announces Anthem, Inc. Adopts Coverage Guidelines for Sacroiliac Joint Fusion Exclusive to the Triangular iFuse Implant System® for Its More Than 40 Million Members

  8/2/2021

  SI-BONE, Inc., a Silicon Valley-based medical device company dedicated to solving musculoskeletal disorders of the sacropelvic anatomy, announced that Anthem, Inc. will cover minimally invasive SI joint fusion exclusively when performed with the iFuse system of triangular titanium implants.

• SI-BONE to Present at the Canaccord Genuity 41st Annual Growth Conference

  7/29/2021

  SI-BONE, Inc., a medical device company dedicated to solving musculoskeletal disorders of the sacropelvic anatomy, announced that the company will be participating in the upcoming Canaccord Genuity 41st Annual Growth Conference.